CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting dated November 3, 2020 with regard to unaudited financial results of the Company for the quarter / half year ended on September 30, 2020 published in Financial Express CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces IND filing of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor Earnings Call for Q2FY21 of Cadila Healthcare
Conference Call with Cadila Healthcare Ltd. Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript. CADILA HEALTHCARE LTD. - 532321 - Unaudited Financial Result For The Quarter/ Half Year Ending September 30, 2020.
Unaudited financial result for the quarter / half year ending September 30, 2020. CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus to present PBC and NASH clinical trial data of Saroglitazar Mg at the AASLD''s The Liver Meeting Digital Experience(tm) 2020 CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst/Institutional Investors' meet CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from USFDA for Dapagliflozin tablets CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from USFDA for Linagliptin Tablets 